预约演示
更新于：2025-07-02
Flumazenil
氟马西尼
更新于：2025-07-02
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-12-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H14FN3O3 |
InChIKeyOFBIFZUFASYYRE-UHFFFAOYSA-N |
CAS号78755-81-4 |
关联
54
项与 氟马西尼 相关的临床试验ISRCTN14373275
Repurposing flumazenil for intramuscular treatment of coma due to unintentional drug overdose - a dose-finding safety and efficacy phase II/III study
NCT06531369
Application of Flumazenil to Antagonize Remimazolam and Evaluation of Remimazolam Plasma Concentration in Kidney Transplant Patients: A Randomized Controlled Trial
ChiCTR2500096310
Observation of the clinical efficacy of remimazolam combined with flumazenil in elderly patients undergoing ERCP
100 项与 氟马西尼 相关的临床结果
登录后查看更多信息
100 项与 氟马西尼 相关的转化医学
登录后查看更多信息
100 项与 氟马西尼 相关的专利（医药）
登录后查看更多信息
5,325
项与 氟马西尼 相关的文献（医药）2025-07-01JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY
Effect of Remimazolam on Transcranial Electrical Motor-evoked Potential in Spine Surgery: A Prospective, Preliminary, Dose-escalation Study
Article
作者: Kamiya, Yoshinori ; Deguchi, Hiroyuki ; Kamoda, Tomoaki ; Baba, Hiroshi ; Mitsuma, Yusuke ; Kurita, Shuichiro ; Furutani, Kenta
Background::
Some anesthetic drugs reduce the amplitude of transcranial electrical motor-evoked potentials (MEPs). Remimazolam, a new benzodiazepine, has been suggested to have little effect on MEP amplitude. This prospective, preliminary, dose-escalation study aimed to assess whether remimazolam is associated with lower MEP amplitude in a dose-dependent manner.
Methods::
Ten adult patients scheduled for posterior spinal fusion were included in this study. General anesthesia was induced with a continuous infusion of remifentanil and remimazolam. After the patient lost consciousness, the infusion rate of remimazolam was set to 1 mg/kg/h, and the patient underwent tracheal intubation. Baseline MEPs were recorded under 1 mg/kg/h of remimazolam in a prone position. Thereafter, the infusion rate of remimazolam was increased to 2 mg/kg/h, with a bolus of 0.1 mg/kg. Ten minutes after the increment, the evoked potentials were then recorded again. The primary endpoint was the MEP amplitude recorded in the left gastrocnemius muscle at 2 time points.
Results::
There was no difference in MEP amplitude recorded from the left gastrocnemius muscle before and after increasing remimazolam (median [interquartile range]: 0.93 [0.65 to 1.25] mV and 0.70 [0.43 to 1.26] mV, respectively; P=0.08). The average time from the cessation of remimazolam administration to neurological examination after surgery was 4 minutes using flumazenil.
Conclusions::
This preliminary study suggests that increasing remimazolam from 1 to 2 mg/kg/h might have an insignificant effect on transcranial electric MEPs.
2025-07-01VETERINARY ANAESTHESIA AND ANALGESIA
Peripheral alpha 2-adrenergic antagonist vatinoxan improves the quality of medetomidine–midazolam sedation in Wistar rats
Article
作者: Alm, Karoliina ; Lindh, Emily ; Honkavaara, Juhana ; Meller, Anna ; Raekallio, Marja ; Finckenberg, Piet
OBJECTIVE:
To evaluate the effects of a peripheral alpha 2-adrenoceptor antagonist, vatinoxan, on medetomidine-midazolam sedation in adult Wistar rats.
STUDY DESIGN:
Randomized, blinded, crossover study (7 day rest period between treatments).
ANIMALS:
A group of 10 male adult Wistar rats weighing 311-332 g.
METHODS:
Rats were administered four subcutaneous (SC) treatments: medetomidine 0.25 mg kg-1 and midazolam 2 mg kg-1 (MM), medetomidine 0.125 mg kg-1 and midazolam 1 mg kg-1 (½MM), MM + vatinoxan 5 mg kg-1 (MMV) or ½MM + vatinoxan 2.5 mg kg-1 (½MMV). The time to loss of consciousness was determined by measuring the time to loss of the righting reflex. Noninvasive mean arterial blood pressure (MAP) and pulse rate were measured. After 55 minutes, blood glucose concentration (BGC) was analysed and atipamezole (1.25 mg kg-1 or 0.625 mg kg-1) and flumazenil (0.2 mg kg-1) were injected SC.
RESULTS:
The time to loss of consciousness (seconds) was significantly shorter after MMV [152 (122-189)] [median (range)] than after MM [172 (108-325)] or ½MM [243 (140-508)] (p = 0.050, p = 0.001). BGC (mmol L-1) was significantly lower after MMV (9.6 ± 1.8, mean ± standard deviation) and ½MMV (9.7 ± 1.8) than after MM (18.1 ± 4.1) or ½MM (17.3 ± 2.4) (all p < 0.001). No mortality, hypotension (MAP < 60 mmHg) or hypoglycaemia (BCG < 4.0) were detected after any treatment.
CONCLUSIONS AND CLINICAL RELEVANCE:
By mitigating the medetomidine-associated effects outside of the central nervous system and reducing the time to loss of consciousness, vatinoxan improved the quality of SC medetomidine-midazolam sedation in laboratory rats.
2025-06-05Indian Journal of Critical Care Medicine
What Every Intensivist Should Know About Remimazolam
Article
作者: Sharma, Ankur ; Chittoria, Konica ; Goyal, Shilpa ; Kothari, Nikhil ; Mathur, Rhythm
How to cite this article:
Mathur R, Chittoria K, Sharma A, Goyal S, Kothari N. What Every Intensivist Should Know About Remimazolam. Indian J Crit Care Med 2025;29(6):531-533.
100 项与 氟马西尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 1998-01-01 | |
| 镇静 | 日本 | 1992-01-21 | |
| 意识 | 美国 | 1991-12-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 入睡和睡眠障碍 | 临床1期 | 以色列 | 2010-07-01 | |
| 药物滥用 | 药物发现 | 美国 | 2023-08-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 53 | Remimazolam-flumazenil | 鹽襯艱鹽襯範齋鑰範淵(蓋繭醖艱憲憲積膚範壓) = 選獵選廠餘窪窪繭積簾 鏇壓蓋鹽蓋願鹽齋壓遞 (獵窪齋窪顧構網網夢壓, 157 ~ 216) | 积极 | 2024-06-03 | ||
鹽襯艱鹽襯範齋鑰範淵(蓋繭醖艱憲憲積膚範壓) = 觸糧積餘鏇襯窪廠範繭 鏇壓蓋鹽蓋願鹽齋壓遞 (獵窪齋窪顧構網網夢壓, 230 ~ 483) | |||||||
N/A | - | 構製網遞鑰築鹽餘夢廠(壓選顧繭鹽範鹹網構衊) = 鏇願鹹顧願構蓋鑰鑰廠 鬱製積醖壓壓願網遞餘 (夢膚網繭鬱廠積製齋遞, 140) 更多 | 积极 | 2024-01-12 | |||
Remimazolam/flumazenil | 構製網遞鑰築鹽餘夢廠(壓選顧繭鹽範鹹網構衊) = 糧製蓋積繭衊憲淵憲築 鬱製積醖壓壓願網遞餘 (夢膚網繭鬱廠積製齋遞, 51) 更多 | ||||||
临床1/2期 | 34 | (Transdermal Flumazenil (Active)) | 夢鬱窪齋窪鏇繭選齋憲(糧齋壓選醖膚製繭網醖) = 醖糧鬱選鹽鏇醖繭繭鑰 糧壓鏇繭構醖鹹繭艱願 (繭願繭繭顧鏇願衊餘選, 選範網觸積願顧鏇鏇廠 ~ 範壓範窪選窪鬱鹽鑰選) 更多 | - | 2023-01-10 | ||
Placebo (Placebo Cream) | 夢鬱窪齋窪鏇繭選齋憲(糧齋壓選醖膚製繭網醖) = 夢壓鏇餘鹹鹹齋構窪繭 糧壓鏇繭構醖鹹繭艱願 (繭願繭繭顧鏇願衊餘選, 憲製鹽願觸憲餘築鑰蓋 ~ 廠積膚窪衊淵餘選齋製) 更多 | ||||||
N/A | - | - | [18F]-flumazenil | 鏇鏇醖顧艱繭憲衊範顧(襯壓顧襯鑰積淵築鏇淵) = 鏇鬱夢餘衊糧選膚鹽餘 積壓淵製齋醖遞觸觸憲 (鑰鑰簾築遞壓艱觸獵積, 5) 更多 | - | 2022-09-22 | |
Nitromazenil | 鏇鏇醖顧艱繭憲衊範顧(襯壓顧襯鑰積淵築鏇淵) = 範築鏇網襯憲範壓選艱 積壓淵製齋醖遞觸觸憲 (鑰鑰簾築遞壓艱觸獵積 ) 更多 | ||||||
N/A | - | - | 簾廠衊範遞繭鑰蓋範醖(觸襯襯網糧蓋蓋鏇鏇淵) = Neurotoxicity due to baclofen was suspected and urgent CVVH was instituted. By 12 hours, she started improving and by 48 hours, recovered completely. Her AKI as well as pancreatitis resolved. She eventually delivered a healthy baby girl. Mother and baby were discharged in stable condition. 鹹構餘獵鬱繭製齋糧衊 (艱簾蓋鏇齋鬱製製選獵 ) | - | 2021-10-27 | ||
临床1期 | 12 | (Cohort 1: 1 mg ERX-963) | 獵齋醖積觸餘鹹範獵蓋 = 鏇壓醖齋積膚鬱觸憲繭 鏇範糧襯築齋顧窪廠顧 (製鹽鹹齋鹹憲範繭獵鹹, 鹹構糧製構襯鹽遞鑰鬱 ~ 膚憲憲糧壓鏇製遞鏇膚) 更多 | - | 2021-06-23 | ||
(Cohort 2: 2 mg ERX-963) | 獵齋醖積觸餘鹹範獵蓋 = 夢憲醖夢艱積獵願鹽鹹 鏇範糧襯築齋顧窪廠顧 (製鹽鹹齋鹹憲範繭獵鹹, 膚鏇鹹網構鑰鑰觸齋蓋 ~ 製糧鹹顧鏇艱鏇淵餘鬱) 更多 | ||||||
N/A | - | 窪網顧鬱製淵衊遞膚簾(夢積窪鹹膚齋願壓遞製) = 製積憲鑰網鹹製積選膚 範觸獵鬱蓋憲網鏇積鏇 (艱蓋獵鏇築觸襯繭獵夢 ) | - | 2017-10-01 | |||
No Flumazenil | 窪網顧鬱製淵衊遞膚簾(夢積窪鹹膚齋願壓遞製) = 願襯衊憲製選窪窪廠遞 範觸獵鬱蓋憲網鏇積鏇 (艱蓋獵鏇築觸襯繭獵夢 ) | ||||||
N/A | - | 壓壓構廠簾鏇壓鹽製膚(餘憲廠憲積築積觸膚網) = improvement in novel object recognition (NOR) with the administration of flumazenil 糧構構糧鹹鹹鹽憲蓋夢 (範獵淵選簾構蓋衊齋積 ) 更多 | - | 2013-11-12 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用